Increased interleukin-10 but unchanged insulin sensitivity after 4 weeks of (1, 3)(1, 6)-beta-glycan consumption in overweight humans

Nutr Res. 2009 Apr;29(4):248-54. doi: 10.1016/j.nutres.2009.03.002.

Abstract

Obesity-induced insulin resistance has been suggested to be a systemic inflammatory condition with activation of the innate immune system. Animal studies indicate that certain dietary fibers such as (1,3)(1,6)-beta-D-glycans (BDG) have potent effects on immune activity such as increasing the antiinflammatory cytokine interleukin-10 (IL-10) and reducing the secretion of inflammatory factors. Therefore, we hypothesized that BDG consumption improves inflammatory markers and insulin sensitivity in overweight and obese subjects with moderately increased levels of C-reactive protein, indicating subclinical inflammation. We screened 180 overweight and obese subjects for moderately increased C-reactive protein levels on 2 or more occasions, in the absence of any signs of acute infection. Twelve of the subjects met all inclusion criteria and were investigated in a randomized, double-blind, placebo-controlled, crossover design for 2 x 4 weeks (washout > or =4 weeks). Subjects ingested capsules containing 3 x 0.5 g of highly purified BDG or 3 x 0.5 g of placebo (waxy maize starch) daily. Maintenance of the normal diet of the participants and the correct intake of the capsules were monitored, using 6 x 3-day food recording and counting of the provided capsules. Predefined outcome measures were BDG-induced changes in pro and antiinflammatory markers in circulating blood and gene expression in adipose tissue and peripheral insulin sensitivity expressed as M value. The BDG consumption for 4 weeks significantly increased both circulating levels and adipose tissue messenger RNA (mRNA) expression of the antiinflammatory cytokine IL-10 in overweight and obese humans. Insulin sensitivity as well as circulating levels and mRNA expression of proinflammatory cytokines were unaffected by BDG treatment. Increased IL-10 after BDG consumption might be a contributing factor to the known beneficial effects of dietary fiber intake.

Trial registration: ClinicalTrials.gov NCT00403689.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Dietary Fiber / pharmacology*
  • Dietary Fiber / therapeutic use
  • Double-Blind Method
  • Drug Administration Schedule
  • Gene Expression
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism*
  • Insulin Resistance*
  • Interleukin-10 / genetics
  • Interleukin-10 / metabolism*
  • Obesity / drug therapy
  • Obesity / metabolism*
  • Overweight / drug therapy
  • Overweight / metabolism*
  • Proteoglycans / administration & dosage
  • Proteoglycans / pharmacology*
  • Proteoglycans / therapeutic use
  • RNA, Messenger / metabolism
  • Receptors, Transforming Growth Factor beta / administration & dosage
  • Receptors, Transforming Growth Factor beta / therapeutic use
  • Starch / pharmacology

Substances

  • Dietary Fiber
  • Proteoglycans
  • RNA, Messenger
  • Receptors, Transforming Growth Factor beta
  • Interleukin-10
  • betaglycan
  • Starch

Associated data

  • ClinicalTrials.gov/NCT00403689